Overview

* CooperCompanies fiscal Q3 revenue rises 6% yr/yr to $1,060.3 mln, meets expectations, per LSEG data

* Non-GAAP diluted EPS up 15% to $1.10, beating analyst expectations, per LSEG data

* Co repurchased $52.1 mln of shares, $163.6 mln remains in buyback program

Outlook

* CooperCompanies raises fiscal 2025 non-GAAP EPS guidance to $4.08 - $4.12

* Company expects Q4 2025 revenue of $1,049 - $1,069 mln

* CVI revenue forecasted at $700- $713 mln for Q4 2025

* CSI revenue projected at $350 - $356 mln for Q4 2025

Result Drivers

* PRODUCT LINE EXIT - CooperSurgical's gross and operating margins were impacted by a product line exit, reducing GAAP margins

* EFFICIENCY GAINS - Non-GAAP gross margin improved by 70 basis points due to efficiency gains and favorable foreign exchange

* REVENUE GROWTH - CooperVision revenue grew 6% driven by strong performance in Toric and multifocal lenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 In-line $1.06 $1.06

Revenue bln bln (14

Analysts

)

Q3 Beat $1.1 $1.07

Adjusted (15

EPS Analysts

)

Q3 EPS $0.49

Q3 Gross 65.0%

Margin

Q3 EBIT 17.0%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Cooper Companies Inc ( COO ) is $94.00, about 21.6% above its August 26 closing price of $73.66

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)